CHI3L1 and Hepatic fibrosis: In summary, serum CHI3L1 levels are associated with the severity of fibrosis in CHC and its progression over time, which is clinically important for monitoring the degree of hepatic fibrosis and thus predicting the clinical outcome in patients with an SVR after treatment with DAAs.